Ester Aparicio Prats
Tècnic/a superior de laboratori
Grup de recerca
Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic.
Impact of Dolutegravir plus Lamivudine as First-Line Antiretroviral Treatment on HIV-1 Reservoir and Inflammatory Markers in Peripheral Blood.
Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.
Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.
Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.